Si è verificato un errore durante il caricamento della pagina.
Il nostro team è stato avvisato ma contattaci tramite il Widget assistenza email se il problema persiste.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | -138,4x - -153,0x | -145,7x |
| Selected Fwd EBIT Multiple | 32,4x - 35,8x | 34,1x |
| Fair Value | ₩2.902 - ₩3.237 | ₩3.069 |
| Upside | -34,4% - -26,9% | -30,6% |
| Benchmarks | Ticker | Full Ticker |
| Kukje Pharma Co., Ltd. | A002720 | KOSE:A002720 |
| JW Lifescience Corporation | A234080 | KOSE:A234080 |
| BCWORLD PHARM. Co., Ltd. | A200780 | KOSDAQ:A200780 |
| Ilyang Pharmaceutical Co.,Ltd | A007570 | KOSE:A007570 |
| Kyung Dong Pharmaceutical Co., Ltd. | A011040 | KOSDAQ:A011040 |
| KUKJEON PHARMACEUTICAL Co., Ltd | A307750 | KOSDAQ:A307750 |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| A002720 | A234080 | A200780 | A007570 | A011040 | A307750 | ||
| KOSE:A002720 | KOSE:A234080 | KOSDAQ:A200780 | KOSE:A007570 | KOSDAQ:A011040 | KOSDAQ:A307750 | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | 3.8% | 3.8% | NM- | -19.5% | -36.1% | NM- | |
| 3Y CAGR | NM- | 8.1% | NM- | -10.2% | -45.0% | -60.8% | |
| Latest Twelve Months | 3973.7% | 19.2% | -69.8% | -11.7% | 122.8% | -120.7% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 1.9% | 16.6% | 0.1% | 6.4% | 2.5% | 3.7% | |
| Prior Fiscal Year | -1.5% | 14.9% | 8.5% | 6.1% | -15.3% | 5.3% | |
| Latest Fiscal Year | 4.3% | 16.1% | 2.0% | 4.1% | 1.4% | 0.3% | |
| Latest Twelve Months | 3.5% | 15.0% | 1.7% | 4.5% | 2.5% | -0.8% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 0.71x | 0.96x | 1.59x | 1.14x | 0.51x | 1.74x | |
| EV / LTM EBITDA | 12.9x | 4.4x | 13.1x | 14.3x | 10.1x | 56.7x | |
| EV / LTM EBIT | 20.2x | 6.4x | 91.6x | 25.1x | 20.3x | -209.7x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | 6.4x | 20.3x | 91.6x | ||||
| Historical EV / LTM EBIT | 44.5x | 71.2x | 89.1x | ||||
| Selected EV / LTM EBIT | -138.4x | -145.7x | -153.0x | ||||
| (x) LTM EBIT | (1,121) | (1,121) | (1,121) | ||||
| (=) Implied Enterprise Value | 155,172 | 163,339 | 171,506 | ||||
| (-) Non-shareholder Claims * | (13,939) | (13,939) | (13,939) | ||||
| (=) Equity Value | 141,233 | 149,400 | 157,567 | ||||
| (/) Shares Outstanding | 50.0 | 50.0 | 50.0 | ||||
| Implied Value Range | 2,826.59 | 2,990.04 | 3,153.49 | ||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 2,826.59 | 2,990.04 | 3,153.49 | 4,425.00 | |||
| Upside / (Downside) | -36.1% | -32.4% | -28.7% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A002720 | A234080 | A200780 | A007570 | A011040 | A307750 | |
| Enterprise Value | 113,497 | 231,413 | 117,882 | 309,495 | 99,906 | 235,039 | |
| (+) Cash & Short Term Investments | 9,932 | 26,465 | 7,143 | 13,036 | 32,582 | 38,582 | |
| (+) Investments & Other | 4,603 | 2,062 | 2,999 | 44,051 | 68,323 | 5,185 | |
| (-) Debt | (29,467) | (65,299) | (86,917) | (114,649) | (36,205) | (57,868) | |
| (-) Other Liabilities | (11) | 0 | 479 | (3,721) | (261) | 161 | |
| (-) Preferred Stock | 0 | 0 | 0 | (1,113) | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 98,555 | 194,641 | 41,585 | 247,099 | 164,345 | 221,100 | |
| (/) Shares Outstanding | 20.4 | 15.5 | 9.3 | 18.0 | 26.9 | 50.0 | |
| Implied Stock Price | 4,840.00 | 12,570.00 | 4,480.00 | 13,750.00 | 6,100.00 | 4,425.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 4,840.00 | 12,570.00 | 4,480.00 | 13,750.00 | 6,100.00 | 4,425.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |